Key facts
- It has raised $3.5M; the latest was Early Stage VC in Jan 2025.
- Notable investors include OurCrowd, Molini Besozzi Marzoli, Fall Line Capital, 2b AHEAD Ventures, BioGiv Excubator — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mermade (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Mermade (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mermade (Biotechnology)
Operator of a biotechnology research tools platform intended to support DNA and RNA synthesis and analysis workflows for research and clinical laboratories. The company offers enzymatic DNA synthesis platforms, molecular biology reagents, and related laboratory tools, enabling medical companies to generate and work with nucleic acid sequences for research, diagnostics, and therapeutic development.
- Sector
- Healthcare
- HQ
- Nes Ziona, Israel
- Founded
- 2021
- Employees
- 9
- Website
- mermade.bio/
- Ownership
- Privately Held (backing)
Mermade (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mermade (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mermade (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.